Literature DB >> 29083122

Abiraterone in Metastatic Prostate Cancer.

Johann de Bono1, Mario Eisenberger2, Oliver Sartor3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29083122     DOI： 10.1056/NEJMc1711029

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  Estimation of Overall Survival with Subsequent Treatment Effect by Applying Inverse Probability of Censoring Weighting in the LATITUDE Study.

Authors:  Yosuke Koroki; Masataka Taguri; Nobuaki Matsubara; Karim Fizazi
Journal:  Eur Urol Open Sci       Date:  2022-01-06

2.  When is crossover desirable in cancer drug trials and when is it problematic?

Authors:  A Haslam; V Prasad
Journal:  Ann Oncol       Date:  2018-05-01       Impact factor: 51.769

3.  Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.

Authors:  Neal Shore; Celestia S Higano; Daniel J George; Cora N Sternberg; Fred Saad; Bertrand Tombal; Kurt Miller; Jan Kalinovsky; XiaoLong Jiao; Krishna Tangirala; Oliver Sartor
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-05-13       Impact factor: 5.455

4.  A detailed characterization of stepwise activation of the androgen receptor variant 7 in prostate cancer cells.

Authors:  Carlos M Roggero; Lianjin Jin; Subing Cao; Rajni Sonavane; Noa G Kopplin; Huy Q Ta; Dede N Ekoue; Michael Witwer; Shihong Ma; Hong Liu; Tianfang Ma; Daniel Gioeli; Ganesh V Raj; Yan Dong
Journal:  Oncogene       Date:  2020-12-15       Impact factor: 8.756
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.